Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 11, 2023, Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of seven posters at the EASL Congress 2023 in Vienna, occurring from June 21 to 24. The posters focus on five liver disease programs, showcasing data that highlights the company's advancements in addressing unmet medical needs in liver and viral diseases. Key presentations include data on Chronic Hepatitis B treatments involving compounds like CAM-E ALG-000184 and siRNA ALG-125755, as well as innovative approaches targeting Hepatocellular Carcinoma. Chairman & CEO Lawrence Blatt expressed optimism about these being potential best-in-class therapies. Detailed information will be made available on their corporate website post-conference.
Aligos Therapeutics (Nasdaq: ALGS) showcased positive results for its thyroid receptor-beta agonist candidate, ALG-055009, during the 15th Paris Hepatology Conference from March 27-29, 2023. The Phase 1 data revealed a favorable safety and pharmacokinetic profile in healthy volunteers and subjects with hyperlipidemia. The study demonstrated low variability and similar bioavailability for both liquid and gelcap formulations, which are set for a Phase 2 study with a regulatory filing anticipated in Q4 2023. These results indicate promising potential for addressing unmet medical needs in liver and viral diseases.